Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 5:15 p.m. ET. The event will be accessible via a live and archived webcast on Glaukos' investor relations website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent devices, launched between 2012 and 2020, and offers pharmaceuticals for corneal health enhancement.

Positive

• Scheduled participation in the prestigious J.P. Morgan Healthcare Conference, which may enhance investor visibility.
• Ongoing focus on innovative therapies, supporting long-term growth potential.

Negative

• None.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent^®, its first MIGS device, in the United States in 2012, its next-generation iStent inject^® device in the United States in 2018 and most recently, its iStent inject W device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005055/en/

Chris Lewis

Sr. Director, Investor Relations & Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When is Glaukos Corporation participating in the J.P. Morgan Healthcare Conference?

Glaukos Corporation will participate in the J.P. Morgan Healthcare Conference on January 11, 2022, at 5:15 p.m. ET.

How can investors access the webcast for the J.P. Morgan Healthcare Conference?

Investors can access the live and archived webcast on Glaukos' investor relations website.

What is the focus of Glaukos Corporation's business?

Glaukos Corporation focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

What innovative surgery has Glaukos pioneered?

Glaukos has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to revolutionize traditional glaucoma treatment.